Homoharringtonine-induced hyperglycemia.

Sylvester, Robert; Lobell, Michael; Ogden, W. S.; Stewart, James A.

doi:10.1200/jco.1989.7.3.392

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following non-hematologic adverse effects on omacetaxine mepesuccinate are the most prominent: fatigue, diarrhea, pyrexia, nausea, headache, asthenia, anorexia, hyperglycemia, injection-site erythema and tachycardia or chest pain [57][58][59][60]. The non-hematological adverse effects are not common [61].…”

Section: Adverse Side-effects Of Omacetaxine Therapymentioning

confidence: 99%

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Novotný¹,

Al‐Tannak²,

Hunáková³

2016

neo

View full text Add to dashboard Cite

Omacetaxine mepesuccinate is a drug approved in 2014 by FDA for the use in CML therapy in patients resistant to at least two thymidine kinase inhibitors (TKIs). It possesses unique mechanism of anticancer activity that is principally different from mechanism of activity of TKIs. Omacetaxine mepesuccinate inhibits protein translation through prevention of the initial elongation step of protein synthesis and its use benefits CML patients possessing the BCR-ABL oncogene. Because of the superior activity of Omacetaxine in patients who became resistant to therapy with TKIs, FDA decided on the accelerated approval of this drug taking its consideration not only its activity as such but also a favorable benefit-to-risk profile in patients included into clinical studies.

show abstract

Section: Adverse Side-effects Of Omacetaxine Therapymentioning

confidence: 99%

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Novotný¹,

Al‐Tannak²,

Hunáková³

2016

neo

View full text Add to dashboard Cite

show abstract

“…The most common nonhematologic toxicities in CML patients treated with omacetaxine mepesuccinate include diarrhea, fatigue, pyrexia, nausea, asthenia, headache, anorexia, hyperglycemia, injection site erythema, and tachycardia/chest pain 59,60,82–84. Recently, a pooled safety analysis in patients with TKI-resistant CML treated using subcutaneous omacetaxine mepesuccinate (1.25 mg/m 2 ) showed an acceptable safety profile in all phases of CML 85.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia

Chen¹,

Li²

2014

OTT

View full text Add to dashboard Cite

In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Omacetaxine mepesuccinate has been recently approved by the US Food and Drug Administration to treat patients with chronic myeloid leukemia who failed to respond to multiple tyrosine kinase inhibitors and/or acquired the BCR-ABL-T315I mutation. In this review, we discuss the use and effectiveness of omacetaxine mepesuccinate in the treatment of chronic myeloid leukemia, with coverage of its pharmacology, mode of action, and pharmacokinetics. We believe that omacetaxine mepesuccinate will be beneficial to many patients with chronic myeloid leukemia who do not respond well to tyrosine kinase inhibitors.

show abstract

New Natural Products in Cancer Chemotherapy

Slichenmyer

Hoff

1990

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Four new and clinically relevant antineoplastic natural products are reviewed. Taxol is derived from the bark of the western yew. It promotes the formation of microtubule bundles which deform the cytoskeleton and interfere with mitosis. Although phase II efficacy testing is incomplete, taxol is effective in the treatment of patients with ovarian carcinoma and has some activity in patients with non-small cell lung cancer and melanoma. It remains untested against several other neoplasms. The chief toxicities of taxol are myelosuppression, mucositis, anaphylactoid reactions, and peripheral neuropathy. Homoharringtonine is the most active and abundant of the cephalotaxine esters derived from the genus Cephalotaxus. This agent appears to act at the ribosome to inhibit protein synthesis and has clinical activity in patients with acute myelogenous leukemia. The dose limiting toxicities of homoharringtonine are hypotension and myelosuppression. SKF 104864 and CPT-11 are derivatives of camptothecin which are still in early clinical trials. They are cytotoxic in vitro, acting through an interaction with topoisomerase I to induce DNA fragmentation. The spectra of activity and toxicity of SKF 104864 and CPT-11 are still undefined. All four of these new natural products offer possibilities for clinical activity for patients with a variety of malignancies.

show abstract

Homoharringtonine-induced hyperglycemia.

Cited by 5 publications

References 11 publications

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia

New Natural Products in Cancer Chemotherapy

Contact Info

Product

Resources

About